38
Views
0
CrossRef citations to date
0
Altmetric
Research Report

Simplifying rules for optimal allocation of preventive care resources

Pages 231-235 | Published online: 09 Jan 2014

References

  • Müller-Riemenschneider F, Reinhold T, Willich SN. Cost–effectiveness of interventions promoting physical activity. Br. J. Sports Med.43(1), 70–76 (2009).
  • Colantonio LD, Martí SG, Rubinstein AL. Economic evaluations on cardiovascular preventive interventions in Argentina. Expert Rev. Pharmacoecon. Outcomes Res.10(4), 465–473 (2010).
  • John J, Wenig CM, Wolfenstetter SB. Recent economic findings on childhood obesity: cost-of-illness and cost–effectiveness of interventions. Curr. Opin Clin. Nutr. Metab. Care13(3), 305–313 (2010).
  • Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term β-adrenergic antagonists after acute myocardial infarction. N. Engl. J. Med.319(3), 152–157 (1988).
  • Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost–effectiveness in a health maintenance organization. Ann. Intern. Med.121(12), 947–952 (1994).
  • Lieu TA, Ray GT, Black SB et al. Projected cost–effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA283(11), 1460–1468 (2000).
  • Malik IS, Bhatia VK, Kooner JS. Cost–effectiveness of ramipril treatment for cardiovascular risk reduction. Heart85(5), 539–543 (2001).
  • Sanders GD, Bayoumi AM, Sundaram V et al. Cost–effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med.352(6), 570–585 (2005).
  • Courbage C. On priority setting in preventive care resources. Health Econ.19(4), 485–490 (2010).
  • Meltzer D. Accounting for future costs in medical cost–effectiveness analysis. J. Health Econ.16(1), 33–64 (1997).
  • Nyman JA. Should the consumption of survivors be included as a cost in cost–utility analysis? Health Econ.13(5), 417–427 (2004).
  • Gandjour A. Consumption costs and earnings during added years of life – a reply to Nyman. Health Econ.15(3), 315–317 (2006).
  • Lee RH. Future costs in cost–effectiveness analysis. J. Health Econ.27(4), 809–818 (2008).
  • Feenstra TL, van Baal PH, Gandjour A, Brouwer WB. Future costs in economic evaluation. A comment on Lee. J. Health Econ.27(6), 1645–1649 (2008).
  • Liljas B, Karlsson GS, Stålhammar NO. On future non-medical costs in economic evaluations. Health Econ.17(5), 579–591 (2008).
  • Kruse M, Sørensen J, Gyrd-Hansen D. Future costs in cost–effectiveness analysis: an empirical assessment. Eur. J. Health Econ.13(1), 63–70 (2010).
  • van Baal PH, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WB. Economic evaluation and the postponement of health care costs. Health Econ.20(4), 432–445 (2011).
  • Hoel M. Allocating health care resources when people are risk averse with respect to life time. Health Econ.12(7), 601–608 (2003).
  • Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat. Med.17(17), 1923–1942 (1998).
  • Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Solberg LI. Prioritizing clinical preventive services: a review and framework with implications for community preventive services. Annu. Rev. Public Health30, 341–355 (2009).
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis.40(5), 373–383 (1987).
  • Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med. Care36(1), 8–27 (1998).
  • Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac re-synchronization therapy for patients with less symptomatic heart failure. Ann. Intern. Med.154(6), 401–412 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.